How Stabilities Studies Get Your mAb Candidate FDA-Approved – Technology Networks

We’ve updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience. You can read our Cookie Policy here.
Monoclonal antibody candidates need extensive stability characterization along their journey to become commercial drugs. This is done to ensure the quality and safety of the final drug for both clinical trials and marketing approval by the Food and Drug Administration (FDA).

Download this infographic to explore: